These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

824 related articles for article (PubMed ID: 32519842)

  • 1. Toward Nanotechnology-Enabled Approaches against the COVID-19 Pandemic.
    Weiss C; Carriere M; Fusco L; Capua I; Regla-Nava JA; Pasquali M; Scott JA; Vitale F; Unal MA; Mattevi C; Bedognetti D; Merkoçi A; Tasciotti E; Yilmazer A; Gogotsi Y; Stellacci F; Delogu LG
    ACS Nano; 2020 Jun; 14(6):6383-6406. PubMed ID: 32519842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How can nanotechnology help to combat COVID-19? Opportunities and urgent need.
    Campos EVR; Pereira AES; de Oliveira JL; Carvalho LB; Guilger-Casagrande M; de Lima R; Fraceto LF
    J Nanobiotechnology; 2020 Sep; 18(1):125. PubMed ID: 32891146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanotechnology Responses to COVID-19.
    Ruiz-Hitzky E; Darder M; Wicklein B; Ruiz-Garcia C; Martín-Sampedro R; Del Real G; Aranda P
    Adv Healthc Mater; 2020 Oct; 9(19):e2000979. PubMed ID: 32885616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 will constantly sweep its tracks: a vaccine containing CpG motifs in 'lasso' for the multi-faced virus.
    Oberemok VV; Laikova KV; Yurchenko KA; Marochkin NA; Fomochkina II; Kubyshkin AV
    Inflamm Res; 2020 Sep; 69(9):801-812. PubMed ID: 32656668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can nanotechnology help in the fight against COVID-19?
    Palestino G; García-Silva I; González-Ortega O; Rosales-Mendoza S
    Expert Rev Anti Infect Ther; 2020 Sep; 18(9):849-864. PubMed ID: 32574081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanotechnology for COVID-19: Therapeutics and Vaccine Research.
    Chauhan G; Madou MJ; Kalra S; Chopra V; Ghosh D; Martinez-Chapa SO
    ACS Nano; 2020 Jul; 14(7):7760-7782. PubMed ID: 32571007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 Vaccine: A comprehensive status report.
    Kaur SP; Gupta V
    Virus Res; 2020 Oct; 288():198114. PubMed ID: 32800805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination.
    Zheng C; Kar I; Chen CK; Sau C; Woodson S; Serra A; Abboud H
    CNS Drugs; 2020 Sep; 34(9):879-896. PubMed ID: 32780300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No small matter: a perspective on nanotechnology-enabled solutions to fight COVID-19.
    Jones GW; Monopoli MP; Campagnolo L; Pietroiusti A; Tran L; Fadeel B
    Nanomedicine (Lond); 2020 Oct; 15(24):2411-2427. PubMed ID: 32873192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 vaccine development and a potential nanomaterial path forward.
    Shin MD; Shukla S; Chung YH; Beiss V; Chan SK; Ortega-Rivera OA; Wirth DM; Chen A; Sack M; Pokorski JK; Steinmetz NF
    Nat Nanotechnol; 2020 Aug; 15(8):646-655. PubMed ID: 32669664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective vaccination of COVID-19 using shRNA-plasmid-LDH nanoconjugate.
    Acharya R
    Med Hypotheses; 2020 Oct; 143():110084. PubMed ID: 32663741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines.
    Salvatori G; Luberto L; Maffei M; Aurisicchio L; Roscilli G; Palombo F; Marra E
    J Transl Med; 2020 Jun; 18(1):222. PubMed ID: 32493510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2.
    Tai W; Zhang X; Drelich A; Shi J; Hsu JC; Luchsinger L; Hillyer CD; Tseng CK; Jiang S; Du L
    Cell Res; 2020 Oct; 30(10):932-935. PubMed ID: 32759966
    [No Abstract]   [Full Text] [Related]  

  • 14. A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice.
    Lu J; Lu G; Tan S; Xia J; Xiong H; Yu X; Qi Q; Yu X; Li L; Yu H; Xia N; Zhang T; Xu Y; Lin J
    Cell Res; 2020 Oct; 30(10):936-939. PubMed ID: 32801356
    [No Abstract]   [Full Text] [Related]  

  • 15. mRNA Vaccines: Possible Tools to Combat SARS-CoV-2.
    Yi C; Yi Y; Li J
    Virol Sin; 2020 Jun; 35(3):259-262. PubMed ID: 32524253
    [No Abstract]   [Full Text] [Related]  

  • 16. Why have nanotechnologies been underutilized in the global uprising against the coronavirus pandemic?
    Uskoković V
    Nanomedicine (Lond); 2020 Jul; 15(17):1719-1734. PubMed ID: 32462968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19 Coronavirus spike protein analysis for synthetic vaccines, a peptidomimetic antagonist, and therapeutic drugs, and analysis of a proposed achilles' heel conserved region to minimize probability of escape mutations and drug resistance.
    Robson B
    Comput Biol Med; 2020 Jun; 121():103749. PubMed ID: 32568687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanotheranostics against COVID-19: From multivalent to immune-targeted materials.
    Hassanzadeh P
    J Control Release; 2020 Dec; 328():112-126. PubMed ID: 32882269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanotechnology versus coronavirus.
    Nat Nanotechnol; 2020 Aug; 15(8):617. PubMed ID: 32764720
    [No Abstract]   [Full Text] [Related]  

  • 20. COVID-19 therapies and vaccine landscape.
    Nat Mater; 2020 Aug; 19(8):809. PubMed ID: 32704138
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 42.